Adam Olszewski MD

New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma thelancet.com/journals/lanha…

Delighted to share our work now published on behalf of all co-authors. Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL. Thank you so much to all international collaborators! ascopubs.org/doi/10.1200/JC…

For systemic #CTCL /MF/SS, @BrownHeme we choose #immunotherapy a lot. Reviewing T-cell containment options: kill'em, poison'em, PD1-knock'em. But really we should be turning them against each other... ncbi.nlm.nih.gov/pmc/articles/P… @OllilaTom #lymsm

🙌TY to all collaborators (@sairah__ahmed, @LNastoupilMD, @uroosaibrahim, @NEpperla, @tvoorheesmd, @lymphomatic etc) & @RutgersCancer fellow Dr McKenna on this #RWE of #CART for rel/ref SOT-PTLD. We describe immunosupression, toxicity & outcomes. @BrJHaem onlinelibrary.wiley.com/doi/10.1111/bj…

East coast friends! @JohnPLeonardMD gave @lymphomatic and I the challenge of debating the utility of CNS prophylaxis in DLBCL. Come learn and watch us duke it out on 04/13 in NYC! Register now: okt.to/7oIirY @GreatDebatesCME #bloodcancer #HematologicMalignancies

Check out our study on function, treatment, and outcomes in nursing home patients w/ DLBCL- a population very challenging to manage! Glad to see this published. This concludes a series of projects on older pts w/ aggressive lymphoma that are very close to my heart! @lymphomatic

@DrLizBrem and I have been working towards figuring out how to solve the conundrum of CNS prophylaxis in #DLBCL through clinical research. It will be great to spar (gently) with arguments pro and con in this @GreatDebatesCME #lymsm

@CharlesMilrod @Jmarksloan @PeterBarthMD @AaronGoodman33 @nihardesai7 @OllilaTom @BrownHospMed @myelomatic @tony_breu @vsanchorawala It is a great poke to unlearn the "leukostasis = leukopheresis" knee-jerk reaction from your board course. Sad this is an area where citations are from the last century.

To @Jmarksloan @PeterBarthMD @AaronGoodman33 @nihardesai7 @OllilaTom @BrownHospMed @lymphomatic @myelomatic @tony_breu @vsanchorawala and other titans of #MedEd- let me know what you think!

Picture this: A young man presents with a WBC of 100k, and you find this 👇 on your evaluation. Why (and how) is this an emergency? 🤔 A #tweetorial 🧵 1/6

Editorial: The demise of Roe v Wade: a hematologist’s perspective loom.ly/MkH8V3g

@hemepathguy @DrAEvens We talk about it in the paper!

@DrAEvens Still stunned that no one seems to recognize the mutated TP53 + MYC category. It is distinctive and has a horrible prognosis.

Defining and treating high-grade B-cell #lymphoma, NOS ashpublications.org/blood/article/… TY to @BrownMedicine @lymphomatic & @BrownUniversity Dr Kurt collab on this review. 2 new classifications out since this was pre-published ~1 year ago but most content still valid/relevant! #lymsm

@DrAEvens @BrownMedicine @BrownUniversity The HGBL now includes “HGBL with 11q aberration” and HGBL with MYC & BCL6 rearrangements. Welcome to the (still “heterogenous and poorly defined”) family!

#COVID19 booster vaccination leads to seroconversion in over 1/2 of patients w/ hematologic malignancies who had undetectable antibodies to the initial vaccine series. The risk of death appears highest in those with undetectable antibodies. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… @OncoAlert

#boosters work for >50% of pts with #lymphoma who did not respond to initial vaccine. On or off treatment. Boosters + #Evusheld have largely eliminated #COVID deaths (in our center) #lymsm @JournalCancer @ASH_hematology doi.org/10.1002/cncr.3…

Register at bit.ly/3GWO3nN to hear the latest research & info on aggressive #lymphoma from Dr. David Scott, @lymphomatic, Dr. Neha Mehta-Shah & Dr. Dan Landsburg at #IUCLS2022! Join us live in Chicago April 29-30! @UChicagoCME

@DiMengyang @sfhYALE @Dr_AmerZeidan Fourth ASH means you now need to start mentoring too!

My first was #ASH18. I gave my first ASH oral presentation and received my first Abstract Achievement Award @lymphomatic This year I will give my third oral at my fourth ASH, also just received my fourth Abstract Achievement Award @sfhYALE @Dr_AmerZeidan Look forward to #ASH21

We detected clonotypic DNA in the CSF of 36% #DLBCL pts @ high CNS relapse risk. (+)CSF = 29% risk of CNS relapse, (-)CSF assay = 0% risk. If validated - maybe a new way to help personalize CNS prophylaxis? doi.org/10.1182/blooda… #lymsm @BloodAdvances @AdaptiveBiotech @BrownHeme

Defining and Treating High-grade B-cell #lymphoma, NOS | @BloodJournal @ASH_hematology ashpublications.org/blood/article/… Happy to publish this review w/ @RIHospital @BrownUCancer @lymphomatic & Dr Kurt on the challenging topic/entity of HGBL-NOS (1st pic below is correct Fig 1). #lymsm

The future of CLL therapy has arrived: our ph2 AVO trial in 1L CLL from @DanaFarber and @BIDMChealth with support from @AstraZeneca and @genentech is now online @TheLancetOncol authors.elsevier.com/a/1dlF45EIIgEB…

@DusetzinaS You have seven days. Including the weekend.